AIM: We examined the feasibility of local intensity-modulated radiation therapy (IMRT) with pelvic irradiation using the simultaneous integrated boost (SIB) technique to treat patients with castration-resistant prostate cancer (CRPC) after several lines of hormonal therapy.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
PATIENTS AND METHODS: Data from 10 consecutive patients with CRPC treated with SIB-IMRT between November 2001 and September 2009 were analyzed retrospectively.
RESULTS: A decline in prostate-specific antigen (PSA) level was observed in all cases after SIB-IMRT. Biochemical progression-free survival at 5 years was 70% with a median follow-up of 33.5 months after SIB-IMRT. All patients completed SIB-IMRT without delay due to acute toxicity. The PSA nadir after first-line hormonal therapy, the PSA before SIB-IMRT, the PSA doubling time before SIB-IMRT and the PSA nadir after SIB-IMRT were significant factors for biochemical progression after SIB-IMRT.
CONCLUSION: SIB-IMRT for patients with CRPC is feasible and has a satisfactory effect in terms of disease control.
Hakariya T, Obata S, Igawa T, Sakai H. Are you the author?
Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan; Department of Radiology and Radiotherapy, Nagasaki prefecture Shimabara Hospital, Nagasaki, Japan.
Reference: Anticancer Res. 2014 Aug;34(8):4261-5.